Get the Stockscreener App
5.76
4.35%
0.24
Pre-market:
5.76
Lyra Therapeutics Inc stock is traded at $5.76, with a volume of 13,656.
It is up +4.35% in the last 24 hours and down -11.74% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$5.52
Open:
$5.53
24h Volume:
13,656
Relative Volume:
0.51
Market Cap:
$9.47M
Revenue:
$770.00K
Net Income/Loss:
$-38.84M
P/E Ratio:
-0.4055
EPS:
-14.2049
Net Cash Flow:
$-43.02M
1W Performance:
-9.57%
1M Performance:
-11.74%
6M Performance:
-3.03%
1Y Performance:
-58.09%
1-Day Range:
$5.53
$5.85
1-Week Range:
$5.52
$6.43
52-Week Range:
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
5.76 | 9.08M | 770.00K | -38.84M | -43.02M | -14.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Will Lyra Therapeutics Inc. stock see insider buyingJuly 2025 Trends & High Conviction Trade Alerts - newser.com
Identifying reversal signals in Lyra Therapeutics Inc.M&A Rumor & High Conviction Trade Alerts - newser.com
Risk adjusted return profile for Lyra Therapeutics Inc. analyzedJuly 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
Will earnings trigger a reversal in Lyra Therapeutics Inc.July 2025 Short Interest & Proven Capital Preservation Methods - newser.com
What indicators show strength in Lyra Therapeutics Inc.Weekly Profit Recap & Accurate Intraday Trade Tips - newser.com
Is Lyra Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Gains Report & Verified Swing Trading Watchlist - newser.com
What valuation multiples suggest for Lyra Therapeutics Inc. stockJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
Is Lyra Therapeutics Inc. stock attractive for long term wealth buildingPortfolio Gains Summary & AI Optimized Trading Strategy Guides - newser.com
How Lyra Therapeutics Inc. stock benefits from global expansionJuly 2025 Review & Low Drawdown Trading Strategies - newser.com
Is Lyra Therapeutics Inc. still worth holding after the dipRate Hike & Low Drawdown Investment Strategies - newser.com
Will Lyra Therapeutics Inc. outperform the marketJuly 2025 Final Week & Weekly Top Performers Watchlists - newser.com
Why Lyra Therapeutics Inc. stock could see breakout soonGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
Can a trend reversal in Lyra Therapeutics Inc. lead to recoveryJuly 2025 WrapUp & AI Enhanced Trading Alerts - newser.com
Price momentum metrics for Lyra Therapeutics Inc. explainedJuly 2025 Closing Moves & Stepwise Trade Execution Plans - newser.com
Is Lyra Therapeutics Inc. stock a bargain at current levelsFed Meeting & Daily Risk Controlled Trade Plans - newser.com
Published on: 2025-10-29 21:52:23 - newser.com
Order flow analysis tools used on Lyra Therapeutics Inc.Portfolio Value Report & Risk Adjusted Swing Trade Ideas - newser.com
How Lyra Therapeutics Inc. stock responds to policy changesPortfolio Performance Summary & Daily Stock Trend Watchlist - fcp.pa.gov.br
Aug Selloffs: Is Lyra Therapeutics Inc. stock a bargain at current levelsJuly 2025 Volume & AI Driven Stock Price Forecasts - Fundação Cultural do Pará
How buybacks impact Lyra Therapeutics Inc. stock valuePortfolio Value Report & Risk Adjusted Buy and Sell Alerts - Fundação Cultural do Pará
Published on: 2025-10-27 05:33:04 - newser.com
Lyra Therapeutics Stock Fell 11% in a Week, What Now? - Trefis
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lyra Therapeutics Inc Stock (LYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Palasis Maria | President & CEO |
Jul 10 '25 |
Sale |
8.91 |
1,565 |
13,944 |
1,098,435 |
| Cavalier Jason | Chief Financial Officer |
Jul 10 '25 |
Sale |
8.91 |
684 |
6,094 |
519,316 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):